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ABSTRACT: We present Ligity, a hybrid ligand-structure-
based, non-superpositional method for virtual screening of
large databases of small molecules. Ligity uses the relative spatial
distribution of pharmacophoric interaction points (PIPs) derived
from the conformations of small molecules. These are compared
with the PIPs derived from key interaction features found in
protein−ligand complexes and are used to prioritize likely
binders. We investigated the eﬀect of generating PIPs using the
single lowest energy conformer versus an ensemble of con-
formers for each screened ligand, using diﬀerent bin sizes for the
distance between two features, utilizing triangular sets of
pharmacophoric features (3-PIPs) versus chiral tetrahedral sets
(4-PIPs), fusing data for targets with multiple protein−ligand
complex structures, and applying diﬀerent similarity measures.
Ligity was benchmarked using the Directory of Useful Decoys-Enhanced (DUD-E). Optimal results were obtained using the
tetrahedral PIPs derived from an ensemble of bound ligand conformers and a bin size of 1.5 Å, which are used as the default
settings for Ligity. The high-throughput screening mode of Ligity, using only the lowest-energy conformer of each ligand, was
used for benchmarking against the whole of the DUD-E, and a more resource-intensive, “information-rich” mode of Ligity,
using a conformational ensemble of each ligand, were used for a representative subset of 10 targets. Against the full DUD-E
database, mean area under the receiver operating characteristic curve (AUC) values ranged from 0.44 to 0.99, while for the
representative subset they ranged from 0.61 to 0.86. Data fusion further improved Ligity’s performance, with mean AUC values
ranging from 0.64 to 0.95. Ligity is very eﬃcient compared to a protein−ligand docking method such as AutoDock Vina: if the
time taken for the precalculation of Ligity descriptors is included in the comparason, then Ligity is about 20 times faster than
docking. A direct comparison of the virtual screening steps shows Ligity to be over 5000 times faster. Ligity highly ranks the
lowest-energy conformers of DUD-E actives, in a statistically signiﬁcant manner, behavior that is not observed for DUD-E
decoys. Thus, our results suggest that active compounds tend to bind in relatively low-energy conformations compared to
decoys. This may be because activesand thus their lowest-energy conformationshave been optimized for conformational
complementarity with their cognate binding sites.
■ INTRODUCTION
Ligand-based virtual screening (LBVS) is underpinned by the
hypothesis that compounds with similar chemical structures
tend to have similar biological activities.1 LBVS methods use
various representations of a small molecule, such as ﬁnger-
prints, chemical topology, 3D shape, pharmacophoric features,
physicochemical properties, or some combination of these.2
These are often captured in a descriptor that is eﬀectively a
feature vector representing the molecule. Such descriptors are
then compared to that of a known biologically active
moleculea “query”using a similarity measure or metric,
yielding a quantitative score of the similarity of the two
molecules. Many similarity measures and metrics, such as
Tanimoto, Cosine, Dice, and Tversky, have been reported in
the literature (see Supporting Information, Schema S1).3−9
Consensus scoring combines the results of multiple LBVS
searches, typically using data fusion methods, and has been
shown to improve the accuracy of virtual screening.10,11 LBVS
can perform well, especially when ﬁnding new hits with the
same chemotype as known actives. Chemical topology-based
descriptors do not take ligand 3D information into account
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and tend to be worse at scaﬀold hopping than 3D approaches.
Many popular shape-based ligand-based methods,12,13 on the
other hand, require an optimal structural superposition before
comparing the ligands, which can be slow.
Figure 1. Ligity algorithm. Note that some processes, ionization and generate PIPs, are repeated because they have diﬀerent implementations
depending on whether their input is a 3D protein−ligand complex or a 2D SMILES molecule. Conformer generation uses the protocol published
by Ebejer et al.49
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In contrast, structure-based virtual screening (SBVS)
methods use information from the 3D structure of the target
protein.14−16 Explicit SBVS methods propose a structural
hypothesis for how a putative inhibitor binds to a target, by
searching for the binding site and optimal binding mode.
Candidate docked solutions are ranked by a scoring function,
which is based on one of four conceptual approaches:
statistical, knowledge-based, force-ﬁeld-based;17 or, more
recently, machine-learning-based.18 Despite incremental ad-
vances, current SBVS scoring functions tend to correlate
poorly with experimental protein−ligand binding aﬃnity.17
SBVS is a widely used computational method for hit
identiﬁcation, and molecular docking often identiﬁes active
submicromolar compounds.19 The success of homology-
model-based SBVS is directly related to the quality of the
model,20 and can be improved by the use of multiple models
instead of one.21 Implicit SBVS methods rely on one or more
3D pharmacophores of active compounds, but they usually
require superposition on a query molecule, which can be
expensive. Implicit SBVS methods include Discovery Studio’s
Catalyst and HipHop,22 LigandScout,23 LS-Align,24
PHASE,25,26 MOE,27 ROCS,12 SHAFTS,28 and WEGA.29
Thus, both LBVS and SBVS have limitations restricting their
predictive abilities.
Hybrid approaches attempt to improve the performance of
virtual screening by combining multiple approaches to
overcome the weaknesses of the separate methods.30,31 Virtual
screening methods can be combined in three ways: (i) in
sequence,32 (ii) in parallel,33 or (iii) as pure hybrid
methodologies.34 In the sequential approach, diﬀerent VS
methods are used one after another in a workﬂow or pipeline,
with the output of one method serving as the input of another.
The idea is to use faster, coarser methods ﬁrst as ﬁlters to
reduce the initial very large numbers of molecules to a subset,
which are then used in more accurate but time-consuming
methods, such as free energy perturbation (FEP).35 In the
parallel approach, several diﬀerent VS methods are run
simultaneously, with the top results of each method being
combined and taken to the next phase. In hybrid approaches,
such as the one presented in this paper, a single method makes
use of information about both the target protein structure and
the active ligand(s) to discriminate between actives and
inactives.
Most hybrid approaches use information such as shape
similarity, volume overlap, or pharmacophoric similarity to one
or more known ligands to guide, or ﬁlter, the output of a
docking program. The use of active ligand information can
improve performance; however, a relatively computationally
expensive docking run is still required.
We were motivated to develop an alignment-free, hybrid
virtual screening method to utilize both ligand and protein
information in a computationally eﬃcient manner. Previous
work has explored individual aspects of this approach.
FuzCav36 uses a 4833-integer vector to describe a protein−
ligand binding site that counts pharmacophoric triplets
assigned to the Cα atomic coordinates of residues lining the
binding site. While FuzCav is a non-superpositional method, it
is mainly used for binding site comparison. The FLAP
approach of Baroni et al.37 describes a common framework
for comparing proteins and ligands, based on GRID38−41
molecular interaction ﬁelds. Local minima in the interaction
ﬁelds for the protein of interest are sampled to create four-
point pharmacophores, against which conformations of ligands
can be searched, on the basis of the GRID atom-type
pharmacophores they contain. FLAP enables fast searching
but does not utilize knowledge about bound ligands. Both
LigandScout23 and Discovery Studio22 can be run as hybrid VS
methods, but they do not develop descriptors and,
furthermore, are dependent on structural superposition,
which can be a relatively expensive process. We hypothesized
that bound ligands, especially if structurally diverse, contain
key information about the energetically most-important
interactions that would be useful in guiding the creation of
pharmacophore-based database queries.
Therefore, we present “Ligity”, a hybrid method that derives
interaction features from experimentally determined structures
of protein−ligand complexes. These interaction “hot-spots” are
mapped to pharmacophoric interaction points, or “PIPs” in the
ligand space. Ligity descriptors are built from triangular or
chiral tetrahedral combinations of these PIPs. Typically, only a
portion of the cognate ligand will be in contact with the
protein structure and Ligity considers only these PIPs when
constructing a query. Candidate ligands (database com-
pounds) are also converted into Ligity descriptors on the
basis of the 3D distribution of pharmacophoric features in their
enumerated low-energy conformational ensembles. In this case,
all PIPs are used in descriptor construction. Thus, Ligity
descriptors for queries will generally be smaller than the Ligity
descriptors of database molecules. We have therefore included
consideration of the asymmetric Tversky similarity measure to
compare descriptors, as this has the useful property that it can
detect similarities even if the number of the features in the two
descriptors diﬀers signiﬁcantly. If there are multiple structures
for the target protein with diﬀerent query (cognate) active
molecules, Ligity fuses the results of each query. Unlike the
hybrid methods in LigandScout and Discovery Studio, Ligity
has the advantage that it does not require structural
superposition to compare two sets of pharmacophores. Our
results show that Ligity performs virtual screening as well as or
better than docking methods, but it is much more computa-
tionally eﬃcient.
■ METHODS
Ligity is a non-superpositional, knowledge-based, virtual
screening method. It uses one or more existing protein−ligand
complexes to construct a query. This is used to ﬁnd
biologically active molecules within a large database of small
molecule conformational ensembles. An overview of how
Ligity works is shown in Figure 1. The Ligity suite of programs
is written in C++ and Python,42,43 and it uses the open source
cheminformatics toolkit RDKit.44 When used for virtual
screening, the main steps of Ligity are as follows:
(1) For each 3D protein−ligand complex used as (part of) a
query, (a) standardize the ionization state of the protein and
cognate ligand in the complex and (b) ﬁnd protein−ligand
interactions based on the maximal distance per interaction type
and corresponding SMARTS45 (SMILES46−48 arbitrary target
speciﬁcation) deﬁnitions for pharmacophoric features, and (c)
for each protein−ligand interaction, ﬁnd the set of PIPs on the
cognate ligand.
(2) For each molecule in the compound database
represented as a SMILES string, (a) standardize the ionization
state of the molecule, using the same rules as for the query
protein−ligand complex; (b) generate low-energy conformers
using the protocol published by Ebejer et al.49 (Brieﬂy, the
number of conformers generated depends on the number of
Journal of Chemical Information and Modeling Article
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rotatable bonds in the ligand, with 50 for 7 or fewer rotatable
bonds, 200 for 8−12 rotatable bonds, and 300 conformers for
more ﬂexible ligands. An initial conformer is generated using
distance geometry and energy minimized using the UFF force
ﬁeld,50 and conformers more similar than 0.35 Å RMSD are
eliminated); and (c) ﬁnd the set of PIPs corresponding to each
conformer.
(3) For the query ligand(s) and compound database PIPs,
generate the corresponding Ligity descriptors. These encode
the distances and pharmacophoric features between all
triangular or chiral tetrahedral combinations of PIPs. The
Ligity descriptor is the multidimensional array that stores the
counts of the component pharmacophorically labeled triangles
or tetrahedra. Each axis in the multidimensional array
corresponds to the distance between a pair of PIPs.
(4) Calculate the similarity between the descriptors for the
query ligand and each conformer in the compound database.
(5) Rank the compound database for each protein−ligand
query by decreasing similarity.
(6) If multiple protein−ligand queries are used, use data
fusion to combine the ranked lists into one ﬁnal list.
Steps 2 and 3, generation of the conformational ensembles
and Ligity descriptors for the database compounds, are
preprocessing steps that need only be carried out once.
Ligity’s Input and Output. There are two main inputs to
the Ligity algorithm: (1) one or more holo protein−ligand
complex structures for the target of interest, the “query”, and
(2) a database of small molecules in SMILES format to be
screened.
When more than one protein−ligand structure is used for
the same target, this represents the “information-rich” mode of
Ligity. We used the screening-PDB, or sc-PDB,51−53 and its
hierarchically clustered binding sites to deﬁne these
information-rich queries; however, the user is free to select
multiple structure queries by other methods. The clustering in
sc-PDB is based on both the Enzyme Commission (EC)
number and the structural similarity of their binding sites, as
deﬁned by SiteAlign.54,55 SiteAlign quantiﬁes the topological
and pharmacophoric features of binding sites using 1D-
ﬁngerprints and attempts to ﬁnd the best alignment of a target
site with the largest query site. Thus, any given cluster of
similar binding sites could be used as input for Ligity. It should
be emphasized here that Ligity does not require that either the
proteins or their holo binding sites should be superimposed,
since Ligity is a non-superpositional method.
The input virtual screening library can consist of simply a list
of SMILES strings describing the small molecules to be
screened. The output of Ligity is a ranked list of all the
molecules in the virtual library, ordered by decreasing
similarity to the triangular (or chiral tetrahedral) Ligity
descriptor(s) of the active cognate ligand(s).
Standardization of the Ionization State. In order to
make chemically meaningful comparisons, we standardize the
ionization states of both the protein-bound ligands and the
small molecules in the compound database by ﬁrst adding
hydrogens using RDKit and then applying in-house rules (see
Table 3.3 in the work by Ebejer56). These transformations
ensure that ionizable groups are consistently charged, e.g.,
deprotonating COOH into COO−. Although this ionization
happens in 3D for the protein-bound cognate ligands and in
2D for the virtual screening library, the same chemical
transformation rules are applied in both cases. The SMARTS
patterns used to treat ionization do not require explicit
hydrogens to be added to the protein.
Conformer Generation. The list of standardized 2D
molecules in the virtual screening database are subjected to our
RDKit-based44 conformer generation protocol49 to generate an
ensemble of low-energy 3D atomic coordinates. As described
earlier in step 2b, the number of low-energy UFF conformers
generated for a given molecule is determined by its number of
rotatable bonds, with at most 300 conformers for the most
ﬂexible compounds.49 Normally, Ligity considers all con-
formers in a molecule’s ensemble, but there is also a “high-
throughput” mode where only the lowest-energy conformer of
the small molecule is used. This makes subsequent steps in the
algorithm take a fraction of the time taken for the full
conformer set (see “Computational Eﬃciency”).
Generation of PIPs. Pharmacophoric models are auto-
matically generated for the standardized 3D protein−ligand
query or queries and the conformers for the molecules in the
virtual library or database. These pharmacophoric models are
represented by a collection of PIPs. These highlight the
interesting parts of the molecule or key features necessary for
molecular recognition of a ligand by the receptor. Ligity
deﬁnes six types of pharmacophoric features57 in the ligands:
hydrophobic, aromatic, hydrogen bond donor (HBD), hydro-
gen bond acceptor (HBA), anion (−), and cation (+) using
SMARTS patterns.
The SMARTS patterns representing pharmacophoric
features are speciﬁed in a feature deﬁnition ﬁle in RDKit (in
BaseFeatures.fdef). These were modiﬁed to specify
the six “PIP types” that are used by Ligity (listed in Table S1 in
the Supporting Information). These rules occasionally generate
duplicate PIPs with the same PIP type and (x, y, z)-
coordinates; in these cases, the duplicates are ﬁltered out to
give a set of unique PIPs describing the molecule’s shape and
pharmacophoric features.
PIP Generation for the Query Protein−Ligand Complex.
In the case of a query protein−ligand complex, we ﬁrst identify
PIPs in the ligand by applying the SMARTS patterns. PIPs are
then discarded if there is no complementary receptor PIP
within a deﬁned distance of the ligand PIP. For example, for a
hydrogen bond acceptor in the bound ligand, there must a
hydrogen bond donor in the protein within 3.9 Å for this
ligand feature for the PIP to be retained. This culling of
features is determined by the feature pairs and distance criteria
shown in Table 1, which are partly assembled from the
literature.58−60 Ligity does not distinguish between weak,
moderate, and strong hydrogen bonds, which are typically
deﬁned using diﬀerent distance intervals.61 Also, Ligity does
not consider less common and weaker π-interactions, such as π
donor−acceptor interactions.62 PIPs are placed at either the
center of an atom or a pseudoatom, as appropriate for the PIP
Table 1. Pharmacophoric Features and Distance Thresholds
Used To Deﬁne Queries in Ligity
interacting receptor−ligand PIP pairs distance threshold (Å)
(hydrophobic, hydrophobic) 4.5
(acceptor, donor) 3.9
(cation, anion) 4.0
(aromatic, aromatic) 4.5
(cation, aromatic) 4.0
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type; e.g., a benzene ring would have an aromatic PIP
positioned at the center of the ring.
For hydrogen bond acceptor and donor interactions, we also
require that the angle between the hydrogen bond donor heavy
atom, its bonded hydrogen atom, and the hydrogen bond
acceptor atom, should form an angle greater than 90°.
This helps to both prioritize and limit the number of
interaction points.
The query protein−ligand complex PIPs are therefore
deﬁned as those ligand PIPs that interact with the protein,
ﬁltering out parts of the ligand that do not contribute directly
to binding to the target, such as solvent-exposed parts of the
ligand. These are typically a subset of all the possible PIPs in a
ligand. This has a key inﬂuence when selecting a similarity
measure. An example of PIP generation for a cognate ligand of
adenosine deaminase is shown in the Supporting Information
(Figure S1).
PIP Generation for Database Compounds. PIPs are
generated for every conformer of each database compound
using the same SMARTS patterns. Database compounds do
not go through the culling step, so for every conformer, all
PIPs are retained. Thus, the size of the set of PIPs for database
compounds tends to be larger than for binding site ligands
from the query protein−ligand complex. While every con-
former of a given molecule has the same number and types of
PIPs, their positions will depend on its atomic coordinates.
Ligity Descriptor Generation. The list of PIPs generated
either for the query or database compound is used to generate
a Ligity descriptor. A descriptor consists of all possible
combinations of sets of 3- or 4-PIPs and is assembled as shown
in Figure 2.
3-PIP Combinations. In the case of 3-PIP combinations,
each triplet describes a triangle whose vertices are the PIP
types (e.g., ⟨donor, acceptor, acceptor⟩), and whose edges
correspond to the distances between those PIPs. Each triangle
is then used to populate a 3D “array”, mapping each of the
three lengths of the triangle’s edges to corresponding indices
that determine which bin should accumulate the count of that
particular PIP triplet combination.
4-PIP Combinations. In the case of 4-PIP combinations,
each quadruplet of PIPs describes a tetrahedron whose vertices
are the four PIP types (e.g., ⟨donor, acceptor, cation,
acceptor⟩) and whose six edges again correspond to the
distances between pairs of PIPs. Tetrahedron counts are stored
in a six-dimensional array, hereafter referred to as a hypercube,
using the lengths of each of the six edges to map to the indices
corresponding to the appropriate bin that accumulates the
counts of PIP types for that speciﬁc tetrahedron.
Ligity Descriptor Bin Sizes. The location of the bin in the
multidimensional array corresponds to the lengths of the edges
of the triangle (3-PIP) or tetrahedron (4-PIP) geometries.
Each bin stores the number of occurrences of every possible
combination of 3-PIP triangle or 4-PIP tetrahedron. The bin
size determines the “resolution” of the Ligity descriptor. If the
maximum distance between two PIPs of a molecule is 15 Å and
a bin size of 1 Å is used, there would be 15 equally sized bins in
any dimension of the descriptor. A very ﬁne bin size, e.g., 0.1 Å,
would give a descriptor with many bins with most bin counters
set to either 0 or 1. On the other hand, a large bin size, of say
30 Å, would result in only one bin with all counters set to the
total number of occurrences of each PIP type combination.
In both 3-PIP and 4-PIP combinations, index determinism is
ensured by sorting the vertex labels into a canonical order,
which ensures that the same 3-PIP triangles or 4-PIP
tetrahedra contribute to the same bin counter. For example,
with 1 Å sized bins, (⟨HBA, HBD, +⟩, ⟨2.6, 3.7, 3.2⟩) and
(⟨HBA, +, HBD⟩, ⟨3.2, 3.7, 2.6⟩) would contribute to the same
bin, ⟨+ , HBA, HBD⟩ with indices ⟨3, 2, 3⟩. When a geometry,
i.e., a triangle or tetrahedron, contains more than one of the
same PIP type (e.g., 3-PIP ⟨HBA, HBD, HBD⟩), the edges for
the pairs containing those identical PIP types are sorted by
length. This guarantees that identical geometries are also
assigned to the same bin counter. For example, using 1 Å sized
bins, the 3-PIP triangles {⟨HBA, HBD, HBD⟩, ⟨3.7, 4.2, 2.1⟩}
and {⟨HBA, HBD, HBD⟩, ⟨2.1, 4.2, 3.7⟩}, would be counted in
the same bin, ⟨HBA, HBD, HBD⟩ with indices ⟨2, 4, 3⟩.
Triangles or tetrahedra having any side shorter than 1.5 Å or
longer than 15 Å are ﬁltered out. The lower-bound ﬁltering
eliminates large numbers of repetitive geometries (such as
those found in a six-membered aliphatic rings). We also ﬁlter
the descriptor to remove 3-PIP and 4-PIP geometries that
appear infrequently (e.g., that occur only once) or those that
are very common (e.g., >10 times). PIP geometries that occur
frequently in all molecules tend not to be useful for
discriminating between actives and decoys.
Chirality Detection. A 4-PIP tetrahedron is chiral if all four
PIP types are diﬀerent. We capture this chirality by calculating
the chiral volume of the tetrahedron after the four PIPs have
been deterministically sorted by their type. Equation 1 gives a
positive or negative volume, which distinguishes between the
chiral forms of the tetrahedron
Figure 2. Relationship between PIPs and the Ligity descriptor. The lengths of the edges of each triangle are mapped to their corresponding indices
in the array of triangle counts. Shown here is a 3-PIP triangle, with features ⟨HBA, HBA, hydrophobic⟩ and edge lengths of ⟨5.8, 6.1, 4.2⟩ mapping
onto a Ligity descriptor that uses an edge-length bin size of 1.0 Å. The blue-bin count will be incremented.
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= ⃗ −
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6 (1)
where a⃗, b⃗, c,⃗ and d⃗ are the Cartesian coordinates of the
vertices of the PIP tetrahedron. As a performance optimization,
we drop the denominator from the volume calculation, as we
only need the sign of the result to distinguish chirality.
Similarity Score. The PIP descriptors for the query and for
a database compound are used to calculate their similarity. We
tested the similarity measures Tanimoto, Dice, Cosine,
Common Counts, and Tversky. The similarity score of a
database compound is taken to be the highest score from all of
its conformers in the conformational ensemble.
The Tversky similarity, Sαβ(A,B), of the Ligity descriptor
counts is shown in Equation 2
α β α β
=
∑
∑ + ∑ + − − ∑αβ
=
= = =
S A B
A B
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(1 ) min( , )
i
n
i i
i
n
i i
n
i i
n
i i
1
1 1 1
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where A is the Ligity descriptor of a protein−ligand query, B is
the Ligity descriptor of a ligand in the virtual library, n is the
number of distance bins in the descriptor, and Ai and Bi are the
counts of PIP geometries in the ith bin. This is the nonbinary
implementation of the Tversky index, designed to work with
integer vectors as opposed to bit vectors. We tested the
Tversky similarity with weights of α = 1, β = 0; α = 0.95, β =
0.05; α = 0.9, β = 0.1; and α = 0.85, β = 0.15. We hypothesized
that the asymmetric Tversky measure would work well
because, unlike symmetric measures such as the Tanimoto
(or Jaccard63) index, it can be used to emphasize substructural
features of a query and would thus help to focus on only those
parts of the query ligand that interact with the protein.
Fusion of Ranked Results. When multiple queries are
available, we fuse the results from the diﬀerent queries into a
single list. This is achieved using the maximum similarity
(MAX-SIM) data fusion method as described by Nasr et al.64
and is shown in Equation 3
= ⃗| ̅ |
÷ ◊÷
S A B B S A B( , ,..., ) max ( , )B
j
j1
(3)
where S is the similarity score, A is the query vector, B is the
vector of the ligand in the multiple lists, Bj is the vector of the
ligand in list j, and |B̅| is the number of structures being
compared. The highest scoring instance of a molecule across
all ranking lists is used in a ﬁnal, single ranking. It should be
noted that other fusion methods, such as exponential
Tanimoto discriminant, have been reported to do slightly
better64 than MAX-SIM, but they are much more complex and
require parameters to be ﬁtted.
Performance Measurement. All receiver operating
characteristic (ROC) curves and area under the ROC curve
(AUC) calculations were performed in the R software
environment for statistical computing and graphics (version
3.0.0)65 using the package ROCR (version 1.0−4).66,67
BEDROC values were calculated using the R package
enrichvs (version 0.0.5).68 For BEDROC, we used an α
value of 20, as suggested by the authors of this method;69 this
means that “80% of the maximum contribution to the
BEDROC comes from the ﬁrst 8% of the list”.
Ligity Parameter Reﬁnement Data Set. There are
several parameters in the Ligity method. To identify optimal
values we selected three targets that are present in both sc-
PDB and DUD-E,70 which is a widely used benchmark set for
evaluating virtual screening methods. DUD-E contains 50
decoy compounds chosen to have similar physicochemical
properties but dissimilar 2D topology, for every active
compound in the set of 22 886 actives, grouped into 102
diverse target sets, with an average of 224 actives per target.
These three targets were adenosine deaminase (ADA), cyclin-
dependent kinase 2 (CDK2), and trypsin I (TRY1), as shown
in Table 2. For the CDK2 and TRY1 receptor sets, we
randomly selected 100 actives and 100 decoys from the DUD-
E sets. For ADA this was not possible, as there are only 93
actives in the DUD-E data set, so we selected all of these and
100 ADA decoys.
Validation Data Sets. To benchmark the two modes of
Ligity, “HTS mode” and “information-rich mode”, we used
DUD-E to create two data sets. These consisted of (i) all of the
targets in DUD-E and (ii) a randomly selected subset of 10
targets from the DUD-E set that were also present in sc-PDB
(2011 release). The focused subset consisted of angiotensin-
converting enzyme (ACE), adenosine deaminase (ADA),
cyclin-dependent kinase 2 (CDK2), coagulation factor X
(FA10), coagulation factor VII (FA7), glucocorticoid receptor
(GCR), human immunodeﬁciency virus type 1 integrase
(HIVINT), human immunodeﬁciency virus type 1 protease
(HIVPR), thrombin (THRB), and trypsin I (TRY1). These
included the three targets described in the previous section
used for Ligity parameter reﬁnement. For each target, we used
the sc-PDB cluster of cognate protein−ligand complexes to
construct information-rich Ligity queries. We removed the few
structures whose ligands caused errors when read by RDKit
and then standardized the ionization state of the remaining
bound ligands. We also standardized the ionization state and
generated conformers for the corresponding actives and decoys
of each target taken from DUD-E using the same stand-
ardization rules. When present, we removed the cognate ligand
in the sc-PDB structure from the corresponding DUD-E
actives set, to eliminate any bias in the method. As might be
expected, a conformer of the cognate ligand tends to score very
highly with the cognate ligand’s Ligity descriptor. This eﬀect
would be accentuated when using the MAX-SIM data fusion
method, which takes the highest score for each virtual library
molecule across all binding pockets for a target. The ﬁnal
benchmarking data set is shown in Table 3. We list the number
Table 2. Targets Used To Identify Optimal Parameter
Values and Data Structures for Ligity, along with Their sc-
PDB Cluster IDs, PDB IDs, and the Number of
Conformers, nc, for the Active and Decoy Sets
a
PDB ID nc
target
sc-PDB
cluster
ID site 1 site 2 site 3
for
actives
for
decoys
adenosine
deaminase
(ADA)
0085 1ndv 2e1w 3km8 6002 6394
cyclin-dependent
kinase 2
(CDK2)
1424 1pxm 2bts 2c6m 6839 6697
trypsin 1 (TRY1) 1463 1bjv 1o3o 3m35 4647 4956
aThree structures of each target were chosen so as to capture the
protein ﬂexibility. Each receptor has a randomly selected subset of
100 active and 100 decoy molecules taken from DUD-E, except ADA,
which has only 93 actives.
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of sc-PDB protein−ligand structures used as queries, the
number of active and decoy compounds, and how many
conformers they have.
In order to compare Ligity to another non-superpositional
ligand-based virtual screening method, we also tested Oxford
Drug Design’s proprietary implementation of ElectroShape 4D
(version 2.0.2).71 The virtual screening study was performed
by using the 3D cognate ligand as an input to ElectroShape 4D
to generate a query descriptor that was used to rank the active
and decoy molecules of each receptor. Similar to Ligity, the
ionization states of the query molecule and the active and
decoy compounds were standardized at physiological pH. This
was particularly important for ElectroShape, as it uses partial
charges in its similarity computation. All Ligity comparisons
were carried out using a single receptor structure, as deﬁned in
DUD-E.
Unless otherwise stated, the following computational
experiments were carried out using the validation data set
described in Table 2. We tested the eﬀects of (1) using 3-PIP
versus 4-PIP combinations for descriptor generation, (2)
varying the descriptor length bin sizes used to count similar
multi-PIP geometries, (3) using diﬀerent similarity measures,
(4) ranking using either single or MAX-SIM fused results, and
(5) using the lowest-energy conformer versus multiple
conformers for each molecule in a virtual library.
■ RESULTS AND DISCUSSION
We present the results in two parts: the ﬁrst discusses our
investigation to identify the optimal parameters for Ligity. The
second part presents the validation of Ligity for virtual
screening using DUD-E.70 The validation was carried out at
two levels: (i) using the HTS mode of Ligity on all of DUD-E
and (ii) using the information-rich mode of Ligity on a
randomly chosen subset of 10 DUD-E targets (ACE, ADA,
CDK2, FA10, FA7, GCR, HIVINT, HIVPR, THRB, and
TRY1). Of these 10, 3 were selected, ADA, CDK2, and TRY1,
for Ligity parameter optimization.
Ligity Parameter Optimization. 3-PIP versus 4-PIP
Descriptors. We found that, in terms of the method’s accuracy
as measured by ROC AUC, the 4-PIP descriptors performed
Table 3. DUD-E Target Datasets Used To Benchmark Ligity, along with Their sc-PDB Clusters, and the Number of Actives
and Decoys, with the Number of Conformers, nc, Given in Parentheses
target sc-PDB cluster ID number of sc-PDB structures number of actives (nc) number of decoys (nc)
angiotensin-converting enzyme (ACE) 0132 9 282 (27 346) 16 900 (1 307 531)
adenosine deaminase (ADA) 0085 20 93 (6 720) 5 450 (371 990)
cyclin-dependent kinase 2 (CDK2) 1424 109 474 (20 480) 27 850 (1 360 619)
coagulation factor X (FA10) 0224 81 537 (39 732) 28 325 (1 799 269)
coagulation factor VII (FA7) 0223 15 114 (9 759) 6 250 (398 145)
glucocorticoid receptor (GCR) 0367 7 258 (8 682) 14 999 (640 882)
human immunodeﬁciency virus
type 1 integrase (HIVINT) 1167 3 98 (5 096) 6 650 (327 474)
human immunodeﬁciency virus
type 1 protease (HIVPR) 0654 166 535 (27 975) 35 750 (2 189 091)
thrombin (THRB) 0830 113 461 (34 936) 27 004 (2 020 395)
trypsin I (TRY1) 0850 74 449 (30 311) 25 980 (1 706 265)
Table 4. Eﬀect of Diﬀerent Similarity Measures on Ligity’s ROC AUC Performance Using the Parameter Optimizaion
Dataseta
AUC
Tversky (1) Tversky (2) Tversky (3) Tversky (4)
query α = 1 α = 0.95 α = 0.9 α = 0.85
target PDB ID β = 0 β = 0.05 β = 0.1 β = 0.15 Tanimoto Cosine Counts
ADA 1ndv 0.791 0.814 0.831 0.839 0.799 0.810 0.791
2e1w 0.904 0.911 0.919 0.927 0.909 0.912 0.904
3km8 0.796 0.790 0.784 0.770 0.672 0.714 0.796
mean 0.830 0.838 0.845 0.845 0.793 0.822 0.830
fusion 0.893 0.913 0.925 0.935 0.912 0.926 0.913
CDK2 1pxm 0.636 0.581 0.541 0.516 0.508 0.530 0.636
2bts 0.700 0.701 0.669 0.634 0.539 0.593 0.700
2c6m 0.575 0.553 0.539 0.522 0.513 0.481 0.575
mean 0.637 0.611 0.583 0.557 0.520 0.535 0.637
fusion 0.634 0.575 0.532 0.508 0.488 0.503 0.576
TRY1 1bjv 0.724 0.511 0.479 0.467 0.412 0.557 0.724
1o3o 0.671 0.456 0.394 0.363 0.300 0.417 0.671
3m35 0.728 0.709 0.663 0.615 0.483 0.687 0.728
mean 0.708 0.559 0.512 0.482 0.398 0.554 0.708
fusion 0.729 0.712 0.662 0.611 0.472 0.687 0.728
aThe best AUC in each row is shown in bold; it can be seen that Tversky with α = 1 and β = 0 performed best. Note that Dice similarity
calculations (not shown) gave identical results to Tanimoto. The mean AUC across all three cognate structure queries for each target is shown, as
well as the AUC of the MAX-SIM fused results over the three individual queries.
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marginally better than 3-PIPs on our parameter optimization
data set (Supporting Information, Figure S2). However, in
terms of storage space, the 3-PIP descriptors are on average
90.75% smaller than the 4-PIP descriptors. This is an
important consideration in virtual screening experiments,
where it is not uncommon to have millions of molecules to
test.
4-PIP descriptors perform better than 3-PIPs for ADA
(average AUC improvement of 0.018) and TRY1 (average
AUC improvement of 0.020). However, there is a decrease in
performance for CDK2, where the 3-PIP descriptor performs
better (average 3-PIP AUC improvement over 4-PIP of 0.028).
The same pattern is observed in the fused results scoring. It is
possible that CDK2’s ligands, which tend to be ﬂat, could be
better captured by the triangular 3-PIP descriptors. However,
given the three-dimensional and chiral nature of ligand binding
sites, Ligity uses 4-PIP descriptors by default.
Descriptor Bin Size. We evaluated the performance of 4-PIP
Ligity descriptors with hypercube bin sizes of 0.5, 1.0, 1.5, and
2.0 Å. The number of query-matching tetrahedra increases
with the bin size. The results are shown in Table S2 of the
Supporting Information. Results indicate that the optimal bin
size may be dependent on the receptor; Ligity performs slightly
better for CDK2 with a bin size of 0.5 Å, while it performs
better with a bin size of 1.5 Å for ADA and TRY1. It is possible
that this observation could be related to the ﬂexibility of the
molecules. CDK2 actives and decoys sets are less ﬂexible, as
measured by the number of rotatable bonds, than the ADA and
Figure 3. Ligity showed little diﬀerence when using only the lowest-energy conformer of the active or decoy molecule (left column). Using the
lowest-energy conformer when fusing the results also exhibited a minimal eﬀect (right column). The performance of the method using only the
lowest-energy conformer is shown with dashed lines, while the performance using the full conformer set is shown with solid lines.
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TRY1 sets (Supporting Information, Figure S3). Larger, more
ﬂexible molecules have many degrees of freedom and a smaller
bin size may not capture similarities between the query and
database molecules adequately. On the other hand, smaller,
less ﬂexible molecules would match a large number of
tetrahedrons if large bins are used because many molecules
would populate the same bins, increasing the false positive rate
and resulting in a decrease in performance. The default value
of the bin size in Ligity was chosen to be 1.5 Å.
Similarity Measures. Using 4-PIP descriptors and a bin size
of 1.5 Å, we investigated the performance of the following
similarity measures, Tanimoto, Cosine, Dice, Counts (simple
counts of common bins), and Tversky (including diﬀerent
values for α and β). In each case, the ability to rank actives
over decoys was assessed by computing the area under the
ROC curve for each optimization data set protein. The results
are presented in Table 4.
The Tanimoto and Dice similarity measures give identical
ROC AUCs (see eqs 2 and 3 in Schema S1 in the Supporting
Information). These two measures are similar in spirit, the only
diﬀerence is that Tanimoto is the ratio of the number of
common features between the two data structures over the
total number of features, while the Dice measure is the ratio of
the total number of common features over the average size of
the features in the two data structures.
Tversky, with α = 1 and β = 0, and Counts give identical
results. This is because Tversky with β = 0 is a special case of
Counts, where the number of common features are divided by
the number of features in the query, which does not vary,
therefore giving the same rankings of actives and decoys. Note
that results are diﬀerent when we consider fused rankings
results: this is because when using the Tversky measure, the
diﬀerent protein−ligand queries will normalize the common
counts between query and database ligand by a diﬀerent
amount.
Table 4 shows that the diﬀerent similarity measures perform
more consistently for ADA than for CDK2 and TRY1. For
CDK2 and TRY1, similarity measures that quantify global
similarity between the query and virtual library molecule, such
as Tanimoto, perform poorly. This can be explained by
considering the number of PIPs in the query compared to the
number of database compound PIPs (Supporting Information,
Figure S4). The number of query PIPs for CDK2 and TRY1 is
smaller than the number of database compound PIPs. In order
to capture this asymmetry, we need a similarity measure that
captures the substructure nature of the query. By setting the α
parameter to 1.0 in the Tversky measure, we place all the
importance on the query PIPs (and eﬀectively ignore ligand’s
PIPs that do not match).
The number of PIPs in the query and the Tversky score
AUCs have a moderate Pearson correlation coeﬃcient (r) of
0.510, p < 0.05. If we remove the 2c6m query, which seems to
be an outlier, from the CDK2 set, the Pearson’s correlation
coeﬃcient improves to r = 0.741, p < 0.05.
Single Versus Fused Results Rankings. As expected, Table
4 also shows that consensus scoring using MAX-SIM data
fusion over the results from multiple queries improves the
performance of Ligity. For example, for ADA using Tversky
with α = 1 and β = 0, the mean AUC was 0.830, while the
fusion AUC was 0.893. Ligity therefore uses MAX-SIM data
fusion methods across multiple protein−ligand complexes by
default.
Using Lowest Energy Conformer versus Conformational
Ensemble. We were interested in testing two diﬀerent ligand
conformer representations, one where we used only the lowest
energy conformer of the molecule and the other where we used
a conformational ensemble of up to a maximum of 300
conformers per molecule. Using a single conformer greatly
increase the speed and reduces the storage requirements of the
method. We tested Ligity using chiral tetrahedral 4-PIPs, a bin
Figure 4. Ligity preferentially selects lower-energy conformers for actives but not for decoys: (a) lower conformer identiﬁers are selected for
actives, rather than what one would expect at random, and (b) there is no diﬀerence between conformer identiﬁers selected for decoys and ones
selected at random.
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Table 5. Performance of Ligity in HTS Mode against the Ligity-Compatible DUD-E Targetsa
ROC AUC BEDROC EF1%
target no. of actives no. of decoys Tanimoto Tversky Tanimoto Tversky Tanimoto Tversky
ABL1 182 10 750 0.563 0.473 0.077 0.077 1.653 2.204
ACE 281 16 877 0.787 0.787 0.336 0.401 12.425 19.525
ACES 453 26 242 0.634 0.645 0.077 0.155 1.766 5.518
ADA 93 5 450 0.724 0.660 0.149 0.147 3.251 3.251
ADA17 532 35 898 0.638 0.728 0.103 0.283 1.317 9.030
ADRB1 247 15 850 0.523 0.647 0.065 0.129 1.619 5.262
ADRB2 231 14 999 0.523 0.589 0.052 0.040 1.735 0.000
AKT1 293 16 450 0.386 0.548 0.039 0.107 2.737 3.080
AKT2 117 6 900 0.511 0.685 0.140 0.194 8.568 8.568
ALDR 159 8 988 0.574 0.610 0.202 0.172 10.747 6.322
AMPC 48 2 845 0.521 0.541 0.049 0.023 0.000 0.000
ANDR 269 14 349 0.722 0.742 0.194 0.354 4.839 24.938
AOFB 121 6 875 0.422 0.464 0.045 0.027 1.652 0.000
BACE1 283 18 100 0.441 0.775 0.017 0.310 0.000 13.062
BRAF 152 9 950 0.612 0.639 0.208 0.165 12.502 5.264
CASP3 199 10 694 0.600 0.734 0.068 0.258 0.502 7.031
CDK2 474 27 838 0.467 0.507 0.021 0.048 0.000 1.055
COMT 41 3 846 0.789 0.889 0.338 0.665 19.447 58.341
CP2C9 120 7 449 0.518 0.634 0.058 0.186 1.660 8.299
CP3A4 170 11 787 0.450 0.493 0.022 0.057 0.000 2.345
CSF1R 166 12 149 0.526 0.542 0.136 0.152 6.031 7.238
CXCR4 40 3 405 0.575 0.722 0.217 0.134 12.665 0.000
DEF 102 5 699 0.732 0.833 0.212 0.379 10.786 15.689
DHI1 330 19 348 0.481 0.595 0.089 0.062 2.422 1.211
DPP4 533 40 941 0.586 0.591 0.154 0.157 4.312 3.937
DRD3 480 34 048 0.484 0.441 0.043 0.046 1.251 0.626
DYR 231 17 196 0.694 0.758 0.210 0.230 6.504 7.371
EGFR 542 35 047 0.593 0.491 0.054 0.037 0.922 0.000
ESR1 383 20 683 0.838 0.861 0.527 0.594 31.281 39.101
ESR2 367 20 199 0.844 0.870 0.563 0.644 20.130 32.644
FA10 537 28 324 0.564 0.674 0.058 0.118 0.930 2.232
FA7 114 6 249 0.762 0.859 0.210 0.332 6.105 8.721
FABP4 47 2 749 0.786 0.744 0.191 0.276 0.000 10.623
FAK1 100 5 350 0.642 0.531 0.111 0.065 2.019 0.000
FGFR1 139 8 698 0.511 0.522 0.036 0.088 0.722 1.445
FKB1A 111 5 799 0.605 0.751 0.162 0.164 8.122 3.610
FNTA 592 51 493 0.411 0.625 0.012 0.132 0.000 4.053
FPPS 85 8 842 0.917 0.985 0.323 0.776 2.360 36.581
GCR 258 14 998 0.805 0.834 0.244 0.324 3.092 8.116
GLCM 54 3 790 0.667 0.685 0.182 0.279 1.873 11.240
GRIA2 158 11 842 0.662 0.684 0.248 0.154 11.392 5.696
GRIK1 101 6 547 0.656 0.668 0.203 0.102 7.978 1.995
HDAC2 185 10 300 0.676 0.734 0.187 0.201 4.318 4.318
HDAC8 170 10 449 0.640 0.819 0.120 0.377 2.946 8.250
HIVINT 100 6 640 0.390 0.554 0.030 0.116 0.000 3.018
HIVPR 535 35 724 0.663 0.872 0.072 0.490 0.187 23.898
HIVRT 338 18 884 0.495 0.475 0.124 0.085 4.443 1.777
HMDH 170 8 750 0.480 0.906 0.068 0.652 2.358 35.963
HS90A 88 4 850 0.635 0.506 0.096 0.083 0.000 3.436
HXK4 92 4 700 0.662 0.803 0.206 0.307 15.192 9.766
IGF1R 148 9 300 0.502 0.575 0.057 0.189 2.037 14.941
INHA 43 2 300 0.493 0.575 0.031 0.045 0.000 0.000
ITAL 138 8 500 0.619 0.465 0.037 0.065 0.000 0.728
JAK2 107 6 500 0.472 0.475 0.073 0.118 2.807 6.549
KIF11 116 6 850 0.755 0.781 0.149 0.219 4.289 2.574
KIT 166 10 449 0.463 0.437 0.045 0.030 0.000 0.000
KITH 57 2 850 0.649 0.838 0.228 0.709 14.069 47.483
KPCB 135 8 699 0.753 0.813 0.220 0.338 8.923 12.641
LCK 419 27 391 0.471 0.437 0.031 0.043 0.000 1.910
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size of 1.5 Å, and Tversky similarity with α = 1 and β = 0.
Surprisingly, we found that using the lowest-energy conformer
rather than the full ensemble had a small eﬀect on the AUC
performance of Ligity (Figure 3). The average diﬀerence in
AUC between all nine individual binding site structure queries
for ADA, CDK2, and TRY1 is 0.003. For fused results, the
average diﬀerence in AUC between the full conformer
ensemble and the lowest energy conformers is 0.011, with
the full conformational ensemble model doing just slightly
better.
Since Ligity performed equally well when using only the
lowest energy conformer, we decided to test whether the
lowest-energy conformers of a molecule scored best when the
full conformational ensemble is used. For any molecule, each
conformer is assigned a unique integer identiﬁer assigned
sequentially to the conformers when sorted by energy. We
investigated whether Ligity picked lower conformer identiﬁers
more often than would be expected by random chance. Not all
molecules have the same number of conformers in their
ensembles, and a random selection is therefore more likely to
pick conformer identiﬁer 1 than conformer identiﬁer 300,
because every molecule will have at least one conformer but
very few will have the maximum possible of 300. Therefore, for
the active and decoy sets for ADA, CDK2, and TRY1, we built
a theoretical probability function for the selection of conformer
identiﬁers (as identiﬁers are generated according to the energy
rank of the conformer).
The model is described in Equation 4
=
∑ = | |P c
N
( )
i
N
C
id
1
1
i
(4)
Table 5. continued
ROC AUC BEDROC EF1%
target no. of actives no. of decoys Tanimoto Tversky Tanimoto Tversky Tanimoto Tversky
LKHA4 171 9 448 0.718 0.694 0.238 0.150 8.203 1.758
MAPK2 101 6 148 0.660 0.670 0.174 0.199 5.988 3.992
MCR 94 5 149 0.816 0.888 0.215 0.454 6.436 19.307
MET 166 11 249 0.566 0.531 0.130 0.065 6.032 0.603
MK01 79 4 550 0.518 0.602 0.121 0.206 5.095 3.821
MK10 104 6 600 0.488 0.489 0.020 0.031 0.962 0.962
MK14 578 35 847 0.511 0.589 0.040 0.064 0.173 0.519
MMP13 572 37 199 0.648 0.753 0.134 0.268 2.446 9.957
MP2K1 121 8 146 0.669 0.569 0.187 0.058 3.293 0.823
NOS1 98 8 028 0.483 0.451 0.109 0.041 3.071 0.000
NRAM 98 6 200 0.853 0.859 0.342 0.290 11.221 3.060
PA2GA 99 5 150 0.793 0.756 0.225 0.153 1.020 3.059
PARP1 508 30 029 0.635 0.692 0.215 0.231 11.234 7.884
PGH1 195 10 798 0.645 0.637 0.077 0.100 0.000 2.050
PGH2 435 23 139 0.716 0.780 0.166 0.291 3.444 9.874
PLK1 107 6 800 0.658 0.531 0.123 0.048 1.871 0.000
PNPH 103 6 946 0.575 0.578 0.161 0.181 4.888 8.799
PPARA 373 19 399 0.783 0.778 0.262 0.280 6.693 7.764
PPARD 240 12 250 0.547 0.544 0.078 0.098 1.665 2.498
PPARG 484 25 299 0.515 0.605 0.055 0.118 0.619 4.955
PRGR 293 15 648 0.740 0.793 0.142 0.318 2.053 14.714
PTN1 130 7 249 0.398 0.538 0.055 0.090 0.000 3.068
PUR2 50 2 700 0.851 0.837 0.281 0.255 7.857 1.964
PYGM 77 3 944 0.403 0.492 0.016 0.137 0.000 3.917
PYRD 111 6 449 0.682 0.710 0.462 0.413 34.027 16.118
RENI 104 6 956 0.720 0.789 0.043 0.138 0.000 0.000
ROCK1 100 6 300 0.347 0.449 0.020 0.084 1.000 4.000
RXRA 131 6 950 0.788 0.900 0.219 0.596 6.091 27.407
SAHH 63 3 450 0.874 0.852 0.598 0.542 35.050 27.084
SRC 524 34 500 0.565 0.477 0.065 0.050 0.382 0.573
TGFR1 133 8 499 0.609 0.639 0.147 0.154 10.565 4.528
THB 103 7 450 0.794 0.762 0.238 0.150 10.614 0.965
THRB 461 27 000 0.605 0.706 0.063 0.166 2.166 5.632
TRY1 449 25 975 0.711 0.815 0.147 0.280 2.898 6.688
TRYB1 148 7 650 0.670 0.670 0.153 0.132 3.378 3.378
TYSY 109 6 745 0.594 0.725 0.071 0.226 0.911 5.468
UROK 162 9 850 0.525 0.650 0.036 0.120 0.000 1.854
VGFR2 409 24 948 0.632 0.578 0.083 0.093 1.465 1.465
WEE1 102 6 150 0.934 0.929 0.789 0.797 59.348 61.294
XIAP 100 5 150 0.752 0.974 0.190 0.897 8.077 51.490
aThe mean (and standard deviation in parentheses) values of ROC AUC using Tanimoto is 0.622 (±0.132), while for Tversky it is 0.671
(±0.142); the mean EF1% using Tanimoto is 5.648 (±8.668), while for EF1% using Tversky it is 9.047 (±12.713).
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where P(cid) is the probability of picking a speciﬁc conformer
with identiﬁer id for all N molecules, N is the total number of
molecules for the receptor (e.g., 93 for ADA actives), and Ci is
the conformational ensemble for the ith molecule. The
probability of picking a conformer identiﬁer that is larger
than the conformer ensemble size for that molecule is zero. In
our theoretical model, every conformer in an ensemble is
equally likely to be picked, regardless of size. (A simpliﬁed
example is oﬀered in Table S3 of the Supporting Information.)
We compare the Ligity ranking of all conformers of N
molecules with 1000 randomly generated rankings of the same
conformers of these N molecules. We generate each of these
1000 random results lists using the probability function in
Equation 4. We then run a Mann−Whitney statistical test for
the conformer identiﬁer selection produced by Ligity against
each of the 1000 random results lists. In Figure 4 we show two
histograms, of the 1000 resulting p-values for the active and
decoy sets for ADA. There is a clear preference for Ligity to
select lower-energy conformers of actives, where most p-values
are below our signiﬁcance level (α) of 0.05 (Figure 4a). In
other words, there is a statistically signiﬁcant diﬀerence
between the conformer identiﬁers picked by Ligity for actives
and a random set of generated conformer identiﬁers. We also
ran a one-sided test, so we speciﬁcally tested for a preference
for lower conformer identiﬁer than the random set. For the
decoy set (Figure 4b) we saw no signiﬁcant preference for
lower conformer identiﬁers as opposed to random selection, as
there are very few p-values smaller than our chosen α (i.e.,
smaller than 0.05). This diﬀerential behavior was observed for
all three targets we used while prototyping Ligity, including
CDK2 and TRY1.
Using only the lowest-energy conformers is suﬃcient for
Ligity to distinguish between actives and decoys. Butler et al.72
found that bioactive conformations are very close to the global
energy minimum: two-thirds of their 99-molecule data set were
within 0.5 kcal/mol of the global energy minimum. They used
“sophisticated QM-based methods to take into account both
the internal energy of the ligand and the solvation eﬀect, and
the application of physically meaningful constraints to reﬁne
the bioactive conformation” and asserted that strain energies
larger than 2 kcal/mol tended to be attributable to structural
determination inaccuracies. Others have argued that the strain
energy of the bound ligand conformation can be higher than
the calculated global minimum for their unbound form, by as
much as 5−15 kcal/mol.73−77 Some have claimed that the
eﬀect of the bioactive conformation on virtual screening
experiments is small.78,79 Indeed in some of these studies,
starting oﬀ with a low-energy conformation instead of the
bioactive conformation yielded little diﬀerence in enrichment.
The importance of any diﬀerences between the bioactive
and solution conformations of ligands on their binding
aﬃnities remains controversial. In this regard, our ﬁndings
are consistent with those of Butler et al.
Validating Ligity Using DUD-E. Ligity was validated in
two ways: (i) using the HTS mode of Ligity against the entire
DUD-E benchmark and (ii) using the information-rich mode
against the 7 + 3 targets of Table 3. All validation studies used
chiral tetrahedral 4-PIP combinations with a bin size of 1.5 Å.
HTS Mode Ligity. When running Ligity against the whole of
DUD-E, we used only a single known protein−ligand complex
to construct our query Ligity descriptor and only the lowest-
energy conformer of the full conformer ensemble of an active
or decoy was used for screening. This is done for computa-
tional eﬃciency, to enable the large-scale evaluation against the
full DUD-E database.
Ligity descriptor generation failed for three of the 102 DUD-
E targets. For CAH2, its very small ligand (triﬂuoromethane
sulfonamide in PDB entry 1BCD) only generated three PIPs,
and thus, 4-PIP descriptors could not be generated for this
query. RDKit was unable to read in the query molecules of
AA2AR and PDE5A. Thus, 99 DUD-E targets were used in
these validation experiments.
Performance was evaluated for the Tanimoto and Tversky
(α = 1 and β = 0) scoring functions using ROC AUC and
enrichment factors at 1%. Table 5 shows the performance of
Ligity against the 99 Ligity-compatible DUD-E targets in HTS
mode. The mean AUC for the ROC curves using the default
Tversky index is 0.671 (slightly better than when using
Tanimoto index, which has an AUC of 0.622). Ligity in HTS
mode performed very well for some targets, with AUCs greater
than 0.85 for COMT, ESR1, ESR2, FA7, FPPS, HIVPR,
HMDH, MCR, NRAM, RXRA, WEE1, and XIAP. For early
enrichment, as measured by the enrichment factor at 1%
(EF1%), we also found that Tversky performed better than
Tanimoto, with an average EF1% of 9.048 versus 5.648,
Table 6. Ligity Results in Information-Rich Mode Using the DUD-E Validation Subseta
receptor mean AUC (±σ) mean BEDROC (±σ) fusion AUC fusion BEDROC
angiotensin-converting enzyme (ACE) 0.779 (±0.070) 0.424 (±0.181) 0.948 0.776
adenosine deaminase (ADA) 0.811 (±0.068) 0.302 (±0.102) 0.894 0.557
cyclin-dependent kinase 2 (CDK2) 0.610 (±0.035) 0.081 (±0.047) 0.643 0.062
coagulation factor X (FA10) 0.700 (±0.050) 0.195 (±0.079) 0.716 0.208
coagulation factor VII (FA7) 0.750 (±0.026) 0.277 (±0.540) 0.809 0.270
glucocorticoid receptor (GCR) 0.790 (±0.094) 0.300 (±0.116) 0.867 0.439
human immunodeﬁciency virus
type 1 integrase (HIVINT) 0.669 (±0.045) 0.173 (±0.068) 0.637 0.139
human immunodeﬁciency virus
type 1 protease (HIVPR) 0.874 (±0.018) 0.584 (±0.057) 0.876 0.527
thrombin (THRB) 0.747 (±0.035) 0.220 (±0.079) 0.752 0.185
trypsin I (TRY1) 0.725 (±0.060) 0.171 (±0.076) 0.778 0.167
mean across all receptors 0.745 (±0.050) 0.273 (±0.135) 0.792 0.333
aIt can be seen that Ligity’s mean ROC AUC is moderate to excellent across all targets and generally improves when using data fusion. Standard
deviation values, σ, are shown in parentheses. The best ROC AUC for each target is in italic.
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respectively (Table 5). This indicates good early enrichment
behavior using Ligity.
Information-Rich Mode Ligity. We would expect Ligity’s
virtual screening performance to improve with queries built
from multiple cognate ligands. To test this, we built Ligity
queries using the cognate ligands taken from the protein−
ligand complexes in each target’s sc-PDB binding site cluster.
This represents the information-rich mode of Ligity, by
capturing as much information from known actives as possible.
We used data fusion on the results by selecting the maximum
score across all separate ranking lists, calculating AUC and
BEDROC values.
In Table 6 we show the mean AUC for the information-rich
mode of Ligity across each individual query run (i.e., each
single sc-PDB ligand−protein complex is a separate query) and
the corresponding standard deviation (σ). The ROC AUC of
the fusion score based on the ranked results of each individual
query is also shown, along with the early enrichment BEDROC
score for each individual query and for the fused approach. The
BEDROC values were calculated using α = 20. Of the 10
receptors tested using Ligity in the information-rich mode, 9
exhibit early enrichment and only CDK2 shows random early
enrichment.
Ligity’s performance across all receptors had mean AUC
values ranging from 0.6 to 0.9. Data fusion improved the AUC
values by more than 0.05 in half the cases and was only
marginally worse than the mean in just one case (HIVINT).
Comparison of Ligity to Existing Methods. In Table 7,
we compare Ligity’s performance to that of two other
methods: another non-superpositional, 3D ligand similarity
search method, ElectroShape, and the published performance
of a protein−ligand docking method, DOCK, for the
information-rich data set. For reference, as well as the
individual query scores of these PDB structures for Ligity,
we also give the data fusion score.
The AUC values for DOCK in Table 7 were taken from
Table S1 of the the Supporting Information reported by
Mysinger et al.,70 where DOCK 3.6 was tested using the same
PDB structure (second column of Table 7) and the same
actives and decoys as deﬁned in DUD-E. We did not compare
performance with that of 2D ﬁngerprints (e.g., Morgan)
because, as the authors of DUD-E state, Daylight80 ﬁngerprints
were used to remove any decoys that were similar to actives,
and they warned that this may create an artiﬁcially favorable
enrichment bias for 2D ﬁngerprinting methods.
Finally, it can be seen that Ligity does slightly better, on
average, than the other 3D methods in Table 7. The results of
Ligity with data-fusion had the highest mean AUC of 0.793,
followed by Ligity without fusion at 0.749, closely followed by
DOCK at 0.744, and then ElectroShape at 0.565. Ligity fused
had slightly worse AUCs than DOCK for CDK2, FA10, FA7,
THRB, and TRY1 but had signiﬁcantly better AUCs for ACE,
ADA, GCR, and HIVPR. For this data set, the highest ROC
AUC is obtained by DOCK for ﬁve targets, Ligity with data
fusion for four targets, and Ligity without data fusion for one
target.
For CDK2, the query receptor for which Ligity does worst
(1h00, AUC = 0.61) was not present in the CDK2 binding-site
cluster in the sc-PDB release that we used. These sc-PDB
clusters contain binding sites that are similar to one another
(above a certain threshold) and only contain structures that
pass a stringent quality ﬁlter. This implies that the 2003-
deposited structure for 1h00 might not be similar enough to
the sc-PDB binding sites we used as queries. For CDK2,
instead we present the average across all the single CDK2 runs,
shown in parentheses. A similar case applied for PDB entry
2ayw of TRY1.
ElectroShape tended to perform poorly for this data set,
outperforming Ligity for only one target, FA7.
Computational Eﬃciency. To determine the computa-
tional eﬃciency of Ligity, we compared it to a popular
protein−ligand docking method, AutoDock Vina81 (refer to
Table 8 for speed-up comparison). The benchmarks were
carried out using 64-bit GNU/Linux Fedora release 28 running
on an Intel Core i7-6700 CPU at 3.40 GHz. A subset of the
ADA DUD-E benchmark was constructed using all 93 actives
Table 7. ROC AUC Comparison of Methods for a Queries
Using Ligity in “Information-Rich Mode”a)
DUD-E target PDB ID ElectroShape DOCK Ligity Ligity fused
ACE 3bkl 0.452 0.716 0.749 0.948
ADA 2e1w 0.714 0.764 0.857 0.897
CDK2 1h00 0.433 0.791 (0.610) 0.644
FA10 3kl6 0.664 0.866 0.716 0.717
FA7 1w7x 0.822 0.879 0.762 0.809
GCR 3bqd 0.521 0.439 0.807 0.869
HIVINT 3nf7 0.578 0.642 0.717 0.637
HIVPR 1xl2 0.495 0.596 0.836 0.877
THRB 1ype 0.646 0.813 0.709 0.752
TRY1 2ayw 0.320 0.934 (0.725) 0.778
mean AUC 0.565 0.744 0.749 0.793
aFor those cases where the speciﬁc PDB ID was not present in the
corresponding sc-PDB clusterCDK2 and TRY1we use all the sc-
PDB query descriptors and report the mean AUC in parentheses.
Entries with the best AUC among the methods that used only one
structure for comparisonDOCK and Ligityare highlighted in
bold. The best AUC for each target is in italic. Ligity with a single
active structure does better than all other methods for 4 out of the 10
DUD-E target classes, and 9 times out of 10 Ligity is better than the
other non-superpositional method, ElectroShape. Note that when
using more than one protein−ligand complex and fusing the results,
with the exception of HIVINT, Ligity does even better (“Ligity
fused”) than when using only one complex (“Ligity”).
Table 8. Ligity Is about 4−5 Orders of Magnitude Times
Faster than Protein−Ligand Docking, Once Its Descriptors
Have Been Precalculated for the Virtual Library Being
Screeneda
method mode
CPU time
(s)
relative speed-
up
AutoDock Vina ﬂexible ligand 12586.8 1.0
Ligity descriptors + VS information-rich 637.3 19.9
Ligity descriptors information-rich 585.9 21.5
Ligity virtual screening information-rich 51.4 244.9
Ligity virtual screening HTS 1.9 6815.3
aThis is exempliﬁed by comparing with the already very eﬃcient
AutoDock Vina with the ADA target from DUD-E. The “information-
rich” mode of Ligity, with multiple conformers per molecule, used a
total of 3074 conformers for the 93 actives and 2287 conformers for
100 randomly selected decoys. The “HTS” mode of Ligity used just
the lowest-energy conformer in each molecule’s conformer ensemble
for each active or decoy.
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and 100 randomly selected decoys. Ligity requires two steps to
run: (i) precalculation of 4-PIP Ligity descriptors for every
conformer of each molecule in the database and (ii)
comparison of these descriptors with the 4-PIP Ligity
descriptor of the query molecule, in this case, ligand
FR233623, residue name FR6, in PDB entry 2e1w. Using
our C++ implementation of Ligity with 3074 active conformers
and 2287 decoy conformers, step i took 9 min 45.9 s, while
step ii took 51.4 s. For the docking run, each active and each
decoy from the ADA subset was converted into PDBQT-
formatted ﬁles. The same compounds were ﬂexibly docked
using AutoDock Vina instructed to use a single core of the
same machine: this took a total of 209 min 46.8 s. Ligity is
therefore about 20 times faster than AutoDock Vina. If the
Ligity 4-PIP descriptor precalculation is excludedthis only
needs to be done once for the database compoundsLigity is
about 245 times faster than AutoDock Vina. In HTS mode,
using only the lowest-energy conformation of the actives and
decoys, Ligity is about 6800 times faster than docking.
■ CONCLUSIONS
Ligity is a fully automated, non-superpositional, pharmaco-
phore-based method with comparable virtual screening
performance to protein−ligand docking methods, while being
much faster (some 2−3 orders of magnitude faster than
AutoDock Vina). Ligity uses protein−ligand complex
structures to build one or more query descriptors based on
the geometric arrangement of the pharmacophoric features
(PIPs) of the interacting parts of the active ligand(s). Using a
subset of DUD-E, we investigated the parameter space of
Ligity to maximize enrichment, including using 3-PIP versus 4-
PIP pharmacophores, diﬀerent bin sizes in the descriptor,
diﬀerent similarity measures, data fusion methods to aggregate
rankings, and the eﬀect of using the single lowest-energy
conformer versus multiple conformers. Optimal results were
found using 4-PIP descriptors, a bin size of 1.5 Å, Tversky
similarity with α = 1, β = 0, and consensus scoring using MAX-
SIM data fusion over the results of the multiple bound ligand
conformations. These are used as the default settings. Ligity
gave slightly better VS performance with ensembles of
conformers for the database molecules, but the improved
speed when using a single lowest-energy conformer provides a
very competitive high-throughput virtual screening “HTS
mode”. Ligity also performed better in terms of recovery of
known actives when multiple ligands bound to the same
protein were combined into an “information-rich” Ligity
descriptor. It would be interesting to study how sensitive
Ligity’s results are to the particular choice of protein−ligand
structures. This would ideally require a combinatorial
examination of all possible sets of protein−ligand binding
cavities, and we believe this would be an interesting follow-up
study.
Ligity could be used in conjunction with explicit structure-
based virtual screening methods, for example by using docked
poses of known actives in either apoprotein X-ray structres or
homology models. We suspect that, in general, however, the
additional structural noise introduced both by subtle variations
in the homology models of the proteins and in the docked
binding modes of the ligand might reduce the predictive
performance of our method.
The novelty of Ligity lies in its descriptor: a three-
dimensional array descriptor for all possible triangular 3-PIP
feature sets and a six-dimensional hypercube descriptor for all
possible chiral tetrahedral 4-PIP combinations. We found the
4-PIP-based Ligity descriptor to perform better than the 3-PIP
variant. Furthermore, receptor ﬂexibility can be incorporated
by using alternative conformations of the holo protein−ligand
complex where there are multiple experimentally resolved
structures or from molecular dynamics simulations. Ligand
ﬂexibility is captured by ensembles of low-energy conformers.
Ligity is also able to distinguish chiral arrangements of
pharmacophoric features using our 4-PIP tetrahedral descrip-
tors. The non-superpositional nature of Ligity’s descriptors
makes it extremely eﬃcient and particularly well-suited for
machine-learning applications.
We found that Ligity preferentially picked low-energy
conformers for active molecules as the highest scoring
conformers on the targets we used to reﬁne the parameters
of the method (CDK2, TRY1, and ADA). We showed that this
preference is statistically signiﬁcant for actives but not for
decoys. We postulate that, although this is still an open
question in the literature, active compounds bind in a relatively
low-energy conformation. This ﬁnding is consistent with the
process of drug discovery. The structure of the active
compounds in the DUD-E data sets will often be the result
of medicinal chemistry optimization, where optimizing binding
aﬃnity is an important goal. One way to achieve this, while low
molecular weight (and thus rule-of-5 compliance) is
maintained, is to minimize any energy penalty for obtaining
the bound conformation. Artiﬁcial decoy molecules have
undergone no such optimization and, thus, would not be
expected to show this eﬀect. This further suggests that this
selection eﬀect will only be observed in retrospective virtual
screening experiments (using benchmark sets consisting of true
positives and putative negatives) but not in prospective ones.
On the basis of the retrospective analysis presented here, we
believe that Ligity has potential as a prospective virtual
screening method that is able to eﬃciently and successfully
screen databases consisting of millions of molecules.
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■ ABBREVIATIONS
3D, three-dimensional; 4D, four-dimensional; 6D, six-dimen-
sional; AA2AR, adenosine A2a receptor; ABL1, tyrosine-
protein kinase ABL; ACE, angiotensin-converting enzyme;
ACES, acetylcholinesterase; ADA, adenosine deaminase;
ADA17, ADAM17; ADRB1, beta-1 adrenergic receptor;
ADRB2, beta-2 adrenergic receptor; AKT1, Serine/threo-
nine-protein kinase AKT; AKT2, serine/threonine-protein
kinase AKT2; ALDR, aldose reductase; AMPC, beta-
lactamase; ANDR, androgen receptor; AOFB, monoamine
oxidase B; AUC, area under the receiver operating character-
istic curve; BACE1, beta-secretase 1; BEDROC, Boltzmann-
enhanced discrimination of receiver operating characteristic;
BRAF, serine/threonine-protein kinase B-raf; CAH2, carbonic
anhydrase II; CASP3, caspase-3; CDK2, cyclin-dependent
kinase 2; COMT, catechol O-methyltransferase; CP2C9,
cytochrome P450 2C9; CP3A4, cytochrome P450 3A4;
CSF1R, macrophage colony stimulating factor receptor;
CXCR4, C-X-C chemokine receptor type 4; DEF, peptide
deformylase; DHI1, 11-beta-hydroxysteroid dehydrogenase 1;
DPP4, dipeptidyl peptidase IV; DRD3, dopamine D3 receptor;
DUD-E, directory of useful decoys enhanced; DYR,
dihydrofolate reductase; EF, enrichment factor; EGFR,
epidermal growth factor receptor erbB1; ESR1, estrogen
receptor alpha; ESR2, estrogen receptor beta; FA10,
coagulation factor X; FA7, coagulation factor VII; FABP4,
fatty acid binding protein adipocyte; FAK1, focal adhesion
kinase 1; FGFR1, ﬁbroblast growth factor receptor 1; FKB1A,
FK506-binding protein 1A; FNTA, protein farnesyltransferase/
geranylgeranyltransferase type I alpha subunit; FPPS, farnesyl
diphosphate synthase; GCR, glucocorticoid receptor; GLCM,
beta-glucocerebrosidase; GRIA2, glutamate receptor iono-
tropic, AMPA 2; GRIK1, glutamate receptor ionotropic kainate
1; HDAC2, histone deacetylase 2; HDAC8, Histone
deacetylase 8; HIVINT, human immunodeﬁciency virus type
1 integrase; HIVPR, human immunodeﬁciency virus type 1
protease; HIVRT, human immunodeﬁciency virus type 1
reverse transcriptase; HMDH, HMG-CoA reductase; HS90A,
heat shock protein HSP 90-alpha; HXK4, hexokinase type IV;
ID, identiﬁer; IGF1R, insulin-like growth factor I receptor;
INHA, enoyl-[acyl-carrier-protein] reductase; ITAL, leukocyte
adhesion glycoprotein LFA-1 alpha; JAK2, tyrosine-protein
kinase JAK2; KIF11, kinesin-like protein 1; KIT, stem cell
growth factor receptor; KITH, thymidine kinase; KPCB,
protein kinase C beta; LBVS, ligand-based virtual screening;
LCK, tyrosine-protein kinase LCK; LEC, lowest-energy
conformer; LKHA4, Leukotriene A4 hydrolase; MAPK2,
MAP kinase-activated protein kinase 2; MAX-SIM, maximum
similarity (data fusion); MCR, Mineralocorticoid receptor;
MET, hepatocyte growth factor receptor; MK01, MAP kinase
ERK2; MK10, c-Jun N-terminal kinase 3; MK14, MAP kinase
p38 alpha; MMP13, matrix metalloproteinase 13; MP2K1, dual
speciﬁcity mitogen-activated protein kinase kinase 1; NOS1,
nitric-oxide synthase, brain; NRAM, neuraminidase; PA2GA,
phospholipase A2 group IIA; PARP1, poly[ADP-ribose]
polymerase-1; PDB, Protein Data Bank; PDE5A, phospho-
diesterase 5A; PGH1, cyclooxygenase-1; PGH2, cyclooxyge-
nase-2; PIP, pharmacophoric Interaction Point; PLK1, serine/
threonine-protein kinase PLK1; PNPH, purine nucleoside
phosphorylase; PPARA, peroxisome proliferator-activated
receptor alpha; PPARD, peroxisome proliferator-activated
receptor delta; PPARG, peroxisome proliferator-activated
receptor gamma; PRGR, progesterone receptor; PTN1,
protein-tyrosine phosphatase 1B; PUR2, GAR transformylase;
PYGM, muscle glycogen phosphorylase; PYRD, dihydroor-
otate dehydrogenase; RENI, renin; RMSD, root-mean-square
deviation; ROC, receiver operating characteristic; ROCK1,
Rho-associated protein kinase 1; RXRA, retinoid X receptor
alpha; SAHH, adenosylhomocysteinase; SBVS, structure-based
virtual screening; SMARTS, smiles arbitrary target speciﬁca-
tion; SMILES, simpliﬁed molecular-input line-entry system;
SRC, tyrosine-protein kinase SRC; TGFR1, TGF-beta receptor
type I; THB, thyroid hormone receptor beta-1; THRB,
thrombin; TRY1, trypsin I; TRYB1, tryptase beta-1; TYSY,
thymidylate synthase; UROK, urokinase-type plasminogen
activator; VGFR2, vascular endothelial growth factor receptor
2; VS, virtual screening; WEE1, serine/threonine-protein
kinase WEE1; XIAP, inhibitor of apoptosis protein 3
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